PHASE-II STUDY OF HIGH-DOSE MEGESTROL-ACETATE IN PATIENTS WITH ADVANCED OVARIAN-CARCINOMA

CHN VEENHOF; MEL VANDERBURG; M NOOY; JG AALDERS; S PECORELLI; CF OLIVEIRA; N ROTMENSZ; JB VERMORKEN

PHASE-II STUDY OF HIGH-DOSE MEGESTROL-ACETATE IN PATIENTS WITH ADVANCED OVARIAN-CARCINOMA

CHN VEENHOF^*, MEL VANDERBURG, M NOOY, JG AALDERS, S PECORELLI, CF OLIVEIRA, N ROTMENSZ, JB VERMORKEN

^*Corresponding author for this work

Faculty of Medical Sciences/UMCG

Research output: Contribution to journal › Article › Academic › peer-review

31 Citations (Scopus)

Abstract

The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.

Original language	English
Pages (from-to)	697-698
Number of pages	2
Journal	European Journal of Cancer
Volume	30A
Issue number	5
Publication status	Published - 1994

Keywords

MEDROXYPROGESTERONE ACETATE
CANCER

Handle.net

Persistent link

Cite this

@article{d87648f9c50342e39dc47256a9270440,

title = "PHASE-II STUDY OF HIGH-DOSE MEGESTROL-ACETATE IN PATIENTS WITH ADVANCED OVARIAN-CARCINOMA",

abstract = "The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.",

keywords = "MEDROXYPROGESTERONE ACETATE, CANCER",

author = "CHN VEENHOF and MEL VANDERBURG and M NOOY and JG AALDERS and S PECORELLI and CF OLIVEIRA and N ROTMENSZ and JB VERMORKEN",

year = "1994",

language = "English",

volume = "30A",

pages = "697--698",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

number = "5",

}

TY - JOUR

T1 - PHASE-II STUDY OF HIGH-DOSE MEGESTROL-ACETATE IN PATIENTS WITH ADVANCED OVARIAN-CARCINOMA

AU - VEENHOF, CHN

AU - VANDERBURG, MEL

AU - NOOY, M

AU - AALDERS, JG

AU - PECORELLI, S

AU - OLIVEIRA, CF

AU - ROTMENSZ, N

AU - VERMORKEN, JB

PY - 1994

Y1 - 1994

N2 - The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.

AB - The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.

KW - MEDROXYPROGESTERONE ACETATE

KW - CANCER

M3 - Article

SN - 0959-8049

VL - 30A

SP - 697

EP - 698

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 5

ER -